Caris Life Sciences, Inc.
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
CAI$24.43-4.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)
| (amounts in thousands, except share and per share data) | Three Months Ended June 30, | Six Months Ended June 30, | ||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenue: | ||||
| Molecular profiling services | $252,254 | $162,924 | $463,053 | $277,006 |
| Pharma research and development services | 11,458 | 18,474 | 16,833 | 25,308 |
| Total revenue | 263,712 | 181,398 | 479,886 | 302,314 |
| Costs and operating expenses: | ||||
| Cost of Services - Molecular profiling services | 81,328 | 65,321 | 154,211 | 126,215 |
| Cost of Services - Pharma research and development services | 2,788 | 2,392 | 4,730 | 5,350 |
| Selling and marketing expense | 53,764 | 42,260 | 98,808 | 82,089 |
| General and administrative expense (see note 9) | 66,548 | 64,367 | 126,257 | 116,486 |
| Research and development expense | 32,358 | 25,047 | 63,672 | 48,114 |
| Total costs and operating expenses | 236,786 | 199,387 | 447,678 | 378,254 |
| Income (Loss) from operations | 26,926 | (17,989) | 32,208 | (75,940) |
| Other expense, net: | ||||
| Interest income | 6,819 | 1,618 | 13,653 | 2,121 |
| Interest expense | (9,228) | (19,208) | (22,037) | (31,990) |
| Changes in fair value of financial instruments | — | (17,870) | — | (50,203) |
| Other expense, net | (25,131) | (18,341) | (25,082) | (18,358) |
| Total other expense, net | (27,540) | (53,801) | (33,466) | (98,430) |
| Loss before income taxes and income tax benefit | (614) | (71,790) | (1,258) | (174,370) |
| Income tax benefit (expense) | (23) | — | 111 | — |
| Net loss | (637) | (71,790) | (1,147) | (174,370) |
| Other comprehensive loss, net of tax: | ||||
| Unrealized loss on available-for-sale securities | (255) | — | (255) | — |
| Foreign currency translation adjustments | (109) | 424 | (152) | 459 |
| Comprehensive loss | (1,001) | (71,366) | (1,554) | (173,911) |
| Net loss attributable to common shareholders: | ||||
| Net loss | (637) | (71,790) | (1,147) | (174,370) |
| Deemed dividend from Series D redeemable convertible preferred stock | — | (384,436) | — | (384,436) |
| Adjustments of redeemable convertible preferred stock to redemption value | — | (60,971) | — | (85,433) |
| Net loss attributable to common shareholders | $(637) | $(517,197) | $(1,147) | $(644,239) |
| Net loss per share attributable to common shareholders, basic and diluted | $(0.00) | $(7.97) | $(0.00) | $(12.80) |
| Weighted-average shares used in computing net loss per share attributable to common shareholders, basic and diluted | 282,888,610 | 64,918,988 | 282,726,214 | 50,348,947 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.